Berlin suspends vaccination with AstraZeneca again

Berlin suspends vaccination with AstraZeneca again

The Berlin authorities have again suspended the use of the AstraZeneca vaccine, and are also planning to discuss the possibility of using the drug from Johnson & Johnson to vaccinate the homeless, reports TOP NEWS.
According to Berlin Health Senator Dilek Kalayci, recommendations from experts from the Permanent Commission on Vaccinations and the Paul Ehrlich Institute for AstraZeneca are awaiting.
“We have decided not to vaccinate people under 60 years of age – regardless of gender – with the AstraZeneca vaccine yet. This is a precautionary measure. Those who have already been vaccinated and who have had no side effects – and we have not had any tragic cases – they have excellent immunity protection, the vaccine, as before, is good. But when new data appear, you need to wait until they are analyzed, “Kalaychi said at a press conference.

There have been earlier reports of sinus thrombosis of the meninges in women younger than 55 years old who received the AstraZeneca vaccine. In this regard, the Berlin clinics Charité and Vivantes have suspended vaccination with this drug.
The senator explained that she perceives the decisions of the clinics as a precautionary measure, adding that “in such times it is impossible to be too careful.”
In addition to Berlin, vaccination with AstraZeneca has also been suspended in Munich.
Berlin authorities are also considering the possibility of vaccinating the homeless with Johnson & Johnson. The vaccine requires only one vaccine, Kalaychi said, and the second is usually difficult to administer for the homeless.

ALSO READ:  A new vaccine against coronavirus will appear in Europe

Authorities in Austria, Germany, France and Italy, and other EU countries have decided to suspend vaccinations with AstraZeneca as a precautionary measure. This is due to the death of a woman vaccinated with AstraZeneca and the development of thromboembolism in another after receiving the vaccine.
In patients from different countries, after vaccination, blood clotting disorders were also revealed. A possible connection between the administration of the drug and the occurrence of such side effects is currently being established by specialists.
Later, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European drug regulator EMA recognized the AstraZeneca vaccine as safe and effective.